Nature Communications (Aug 2024)

Antibodies utilizing VL6-57 light chains target a convergent cryptic epitope on SARS-CoV-2 spike protein and potentially drive the genesis of Omicron variants

  • Qihong Yan,
  • Xijie Gao,
  • Banghui Liu,
  • Ruitian Hou,
  • Ping He,
  • Yong Ma,
  • Yudi Zhang,
  • Yanjun Zhang,
  • Zimu Li,
  • Qiuluan Chen,
  • Jingjing Wang,
  • Xiaohan Huang,
  • Huan Liang,
  • Huiran Zheng,
  • Yichen Yao,
  • Xianying Chen,
  • Xuefeng Niu,
  • Jun He,
  • Ling Chen,
  • Jincun Zhao,
  • Xiaoli Xiong

DOI
https://doi.org/10.1038/s41467-024-51770-3
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Continued evolution of SARS-CoV-2 generates variants to challenge antibody immunity established by infection and vaccination. A connection between population immunity and genesis of virus variants has long been suggested but its molecular basis remains poorly understood. Here, we identify a class of SARS-CoV-2 neutralizing public antibodies defined by their shared usage of VL6-57 light chains. Although heavy chains of diverse genotypes are utilized, convergent HCDR3 rearrangements have been observed among these public antibodies to cooperate with germline VL6-57 LCDRs to target a convergent epitope defined by RBD residues S371-S373-S375. Antibody repertoire analysis identifies that this class of VL6-57 antibodies is present in SARS-CoV-2-naive individuals and is clonally expanded in most COVID-19 patients. We confirm that Omicron-specific substitutions at S371, S373 and S375 mediate escape of antibodies of the VL6-57 class. These findings support that this class of public antibodies constitutes a potential immune pressure promoting the introduction of S371L/F-S373P-S375F in Omicron variants. The results provide further molecular evidence to support that antigenic evolution of SARS-CoV-2 is driven by antibody mediated population immunity.